Clinical trials: CVD Risk
Ischemia-Reperfusion Injury, Kidney Diseases
Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8.
- Trial name
- NCT00248040
- Testing
- Reparixin continuous infusion, reparixin intermittent infusion
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Dompé Farmaceutici S.p.A
Cerebrovascular Diseases, Stroke
Computer-Aided Prevention System
Stroke is one of the most frequent and life-threatening diseases in Europe. About four stroke events occur per day in Luxembourg alone, and about 30% of these patients are affected by recurrent stroke within the following five…
- Conditions
- Cerebrovascular Diseases, Stroke, Cardiovascular Diseases, CVD Risk Factors
- Trial name
- CAPSYS (NCT02444715)
- Testing
- Standard care, CAPSYS
- Volunteers
- 94 people
- Sponsor
- Lübomira Spassova
Blood Pressure, Hypertension
PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor
Program to Avoid Cerebrovascular Events through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor (PACESETTER) aims to assess the incorporation of its stroke intervention into 2 safety net/academic health…
- Conditions
- Blood Pressure, Hypertension, Mhealth
- Trial name
- NCT03401489
- Testing
- PACESETTER
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Northern California Institute of Research and Education
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.
- Trial name
- NCT01313676
- Testing
- fluticasone furoate/vilanterol, fluticasone furoate, vilanterol
- Where
- 1,611 sites in United States, Argentina and 42 more
- Volunteers
- 16,568 people
- Sponsor
- GlaxoSmithKline
Aortic Stenosis
PARTNER II Trial: S3iCAP
Following completion of enrollment in the PARTNER II SAPIEN 3 intermediate risk trial, this trial provided continued access to treatment for subjects with severe aortic stenosis who were at intermediate surgical risk.
- Trial name
- PII S3i CAP (NCT02687035)
- Testing
- SAPIEN S3 valve
- Where
- 56 sites in United States, Canada
- Volunteers
- 1,822 people
- Sponsor
- Edwards Lifesciences
Obesity, Venous Thrombosis
Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
Deep vein thrombosis(DVT) is a common complication in hospitalized medical patients. Consensus guidelines recommend using medications such as heparin or low-molecular-weight heparins (LMWH) to prevent DVT in these patients.
- Conditions
- Obesity, Venous Thrombosis, Anticoagulants
- Trial name
- NCT00585182
- Testing
- Enoxaparin 0.5 mg/kg once daily
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Utah
Critical Aortic Stenosis
THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial
The purpose of this study is to determine the safety and effectiveness of the device and delivery systems (transfemoral and transapical) in high risk, symptomatic patients with severe aortic stenosis.
- Trial name
- PARTNER (NCT00530894)
- Testing
- Edwards SAPIEN Transcatheter Heart Valve, Surgical Valve Replacement, medical management and/or balloon aortic valvuloplasty
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,057 people
- Sponsor
- Edwards Lifesciences
Symptomatic Severe Aortic Stenosis
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7
The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic…
- Trial name
- PII S3HR/NR7 (NCT03222141)
- Testing
- TAVR Implantation of the THV Prosthesis
- Where
- 40 sites in United States, Canada
- Volunteers
- 583 people
- Sponsor
- Edwards Lifesciences
Diabetic Retinopathy
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various…
- Trial name
- NCT00542178
- Testing
- Hypoglycemic Agents, Standard glycemia control, Intensive BP treatment
- Where
- 7 sites in United States, Canada
- Volunteers
- 3,472 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Neoplasms
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein…
- Trial name
- NCT02555878
- Testing
- Rivaroxaban
- Where
- 151 sites in United States, Belgium and 8 more
- Volunteers
- 841 people
- Sponsor
- Janssen Research & Development, LLC
Obesity, Overweight
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and…
- Trial name
- NCT01601704
- Testing
- NB32, PBO, Weight Management Program
- Where
- 224 sites in United States
- Volunteers
- 8,910 people
- Sponsor
- Orexigen Therapeutics, Inc
Sars-CoV2, COVID
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than…
- Trial name
- NCT04401293
- Testing
- Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
- Where
- 6 sites in United States
- Volunteers
- 257 people
- Sponsor
- Northwell Health
Hypotension, Pressure Ulcer
Comparison of Nasal and Forehead Oximetry in Critically Ill Patients at Risk for Decreased Peripheral Perfusion
Continuous pulse oximetry monitoring is the standard of care in critically ill patients in emergency departments, operating rooms and intensive care units.
- Trial name
- NCT02382133
- Testing
- Nasal alar oxygen sensor
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Washington University School of Medicine
Metastatic Cancers, Multiple Myeloma
Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer
Vertebral augmentation with radiotherapy to increase the functional status and quality of life for patients with vertebral body metastatic cancers.
- Conditions
- Metastatic Cancers, Multiple Myeloma, Vertebral Fracture
- Trial name
- NCT02376933
- Testing
- Vertebroplasty, Radiotherapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Arizona
Cardiovascular Diseases, Statin Adverse Reaction
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are…
- Trial name
- CLEAR Outcomes (NCT02993406)
- Testing
- Bempedoic acid 180 mg tablet
- Where
- 1,319 sites in United States, Argentina and 30 more
- Volunteers
- 13,970 people
- Sponsor
- Esperion Therapeutics, Inc.
Paroxysmal Atrial Fibrillation
Oral Anticoagulation Therapy Pilot Study
The objective of this study is to determine the safety of discontinuing oral anticoagulation therapy in high risk patients who have had a successful cardiac ablation and remain AF recurrence free for 3 months post ablation.
- Trial name
- OAT (NCT01959425)
- Testing
- Off OAT Group (Test), On OAT Group (Control)
- Volunteers
- 80 people
- Sponsor
- Biosense Webster, Inc.
Myocardial Ischemia, Rheumatic Diseases
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Ischemic heart disease (IHD) and its treatment carry profound public health and economic implications. Among Veterans, IHD represents one of the most common causes of death and disability, with over 500,000 affected individuals'…
- Trial name
- SEPPRMACI-ARM (NCT02694185)
- Testing
- Caplan IVR
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 5,269 people
- Sponsor
- VA Office of Research and Development
Abdominal Aortic Aneurysm, Iliac Aneurysm
Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients
The purpose of this study is to assess the role of abdominal aneurysm and iliac aneurysm exclusion using an endovascular prosthesis.
- Conditions
- Abdominal Aortic Aneurysm, Iliac Aneurysm, Internal Iliac Aneurysm
- Trial name
- NCT00583414
- Testing
- Endovascular Aneurysm Repair
- Where
- United States
- Volunteers
- 401 people
- Sponsor
- The Cleveland Clinic
Atrial Fibrillation, Heart Failure
Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure
The purpose of this study is to characterize the feasibility and impact of a diagnostic tool that may help clinicians identify when patients are at higher risk of visiting the hospital for a heart failure event.
- Trial name
- IDENTIFY-HF (NCT01486316)
- Testing
- Reveal XT® Insertable Cardiac Monitor, Heart Failure Risk Status Diagnostic
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hypercholesterolemia, Dyslipidemia
Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors
This is a sixteen-week follow-on and 28 week single-blind extension study for patients who participated in study NK-104-304.
- Conditions
- Hypercholesterolemia, Dyslipidemia, Coronary Heart Disease
- Trial name
- NCT00344175
- Testing
- pitavastatin, simvastatin
- Where
- 28 sites in Denmark, Netherlands and 2 more
- Volunteers
- 178 people
- Sponsor
- Kowa Research Europe